Neurona Therapeutics has announced updated clinical data from its ongoing Phase I/II clinical trial of NRTX-1001, a regenerative cell therapy for the treatment of drug-resistant mesial temporal lobe epilepsy (MTLE). The data reveals a significant reduction in seizure frequency, with more than 90% reduction observed in the first two patients at five- and nine-months post-treatment. The treatment was also found to be well-tolerated, with no serious or severe adverse events reported. Additionally, neuropsychological testing indicated an improvement in memory function in the first patient. The trial is ongoing, and patients are being recruited at epilepsy centres across the United States. NRTX-1001 is a one-time dose of interneurons derived from human stem cells, designed to silence seizure activity in the epileptic region of the brain.
